Josh Bilenker (Jeff Rumans for Endpoints @ JPM 2020)

Josh Bilenker’s team at Eli Lil­ly chops 3 can­cer drug pro­grams in pipeline cleanup as their $1.6B IL-10 ef­fort flames out

Eli Lil­ly cut 3 ear­ly and mid-stage can­cer drug pro­grams from the pipeline to­day, 3 weeks af­ter the new on­col­o­gy team un­der Josh Bilenker nixed an al­liance it had un­der­way in the field with NextCure.

I’m still lin­ing up the drugs with the pro­gram, but the tar­gets make for an in­ter­est­ing list.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.